nvestor presentation First six months of 2019 Slide 3 SEC), including this presentation as well as the company’s statutory Annual Report 2018 and ion of the Annual Report 2018, and written information released, or oral statements made, to nts. Words such as ‘believe’, ‘expect’, ‘may’, ‘will’, ‘plan’, ‘strategy’, ‘prospect’, ‘foresee’, eaning in connection with any discussion of future operating or financial performance identify limited to: ted to Novo Nordisk’s products, product research, product development, product introductions ngs per share, capital expenditures, dividends, capital structure, net financials and other gencies such as legal proceedings, and forward-looking statements involve inherent risks and uncertainties, both general and specific. esentation, could cause actual results to differ materially from those contemplated in any tical and economic conditions, including interest rate and currency exchange rate fluctuations, interruptions of supplies and production, product recalls, unexpected contract breaches or ucts, introduction of competing products, reliance on information technology, Novo Nordisk’s proceedings and investigations, changes in governmental laws and related interpretation n testing, approval, manufacturing and marketing, perceived or actual failure to adhere to , unexpected growth in costs and expenses, failure to recruit and retain the right employees, sults or the accuracy of forward-looking statements in this presentation, reference is made to in the Annual Report 2018. or revise any forward-looking statement after the distribution of this presentation, whether as tes only y only
Download PDF file